TITLE

Titration of antihypertensive agents after their initiation: an important clinical issue now addressed

AUTHOR(S)
Yu Jiang, Johnny; C. S. Wong, Martin
PUB. DATE
November 2011
SOURCE
Heart;Nov2011, Vol. 97 Issue 21, p1721
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
No abstract available.
ACCESSION #
67612439

 

Related Articles

  • Titration of antihypertensive agents after their initiation: an important clinical issue now addressed. Yu Jiang, Johnny; C. S. Wong, Martin // Heart;Nov2011, Vol. 97 Issue 21, p1721 

    The authors reflect on the effectiveness of antihypertensive agents to control the cardiovascular diseases in the U.S. They suggest that the contribution of medical costs in treatment of cardiovascular diseases like stroke is 17 percent of total healthcare expenditure on the basis of report...

  • Implications of the forecast of cardiovascular disease in the United States in the next 20 years. Beller, George // Journal of Nuclear Cardiology;Apr2011, Vol. 18 Issue 2, p199 

    No abstract available.

  • Angiotensin receptor blockers: clinical relevance and new opportunities. Volpe, Massimo // Hot Topics in Hypertension;2012, Vol. 5 Issue 14, p7 

    Effective treatment of high blood pressure (BP) is a key strategy for reducing the burden of hypertension-related cardiovascular diseases, ie, mainly stroke, myocardial infarction, heart failure, and cardiovascular death. Despite these well-established concepts, however, hypertension remains...

  • Azilsartan: a new angiotensin receptor blocker. Kaschina, Elena; Unger, Thomas // Hot Topics in Hypertension;2012, Vol. 5 Issue 14, p15 

    Azilsartan medoxomil (AZL-M) is characterized by a high binding potency to the AT1 receptor, with half-maximal inhibitory concentration in the low nanomolar range for inhibiting specific binding of angiotensin II to the receptor. Pharmacodynamic studies showed that AZL-M structure determines its...

  • Current challenges in the clinical management of hypertension: recent studies on azilsartan. Segura, Julián; Ruilope, Luis M. // Hot Topics in Hypertension;2012, Vol. 5 Issue 14, p21 

    Arterial hypertension is the most frequent cause of death in the general population. Renin-angiotensin system suppression is a widely used therapy in hypertensive patients due to its blood pressure lowering efficacy and the capacity to prevent and regress target organ damage. Azilsartan...

  • Changes in drug therapy following hospital discharge for patients in a general practice: a German incident study. Müller-Bühl, Uwe; Gerold, Carolin; Engeser, Peter; Szecsenyi, Joachim // Journal of Public Health (09431853);Jun2009, Vol. 17 Issue 3, p217 

    In primary care, clinically recommended drug medication is often modified after hospitalization. The aim of the study was to examine the frequency and factors associated with GPs changing the hospital drug treatment in a sample of patients discharged from the hospital. In a prospective study,...

  • Telmisartan: A Review of its Use in Cardiovascular Disease Prevention. Frampton, James E. // Drugs;2011, Vol. 71 Issue 6, p651 

    Telmisartan (Micardis®, Pritor®), a well established angiotensin type 1 receptor antagonist, is indicated in the EU for the reduction of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease (CVD) or type 2 diabetes mellitus with documented target organ...

  • Are the Pleiotropic Effects of Telmisartan Clinically Relevant? Rizos, C. V.; Elisaf, M. S.; Liberopoulos, E. N. // Current Pharmaceutical Design;8/21/2009, Vol. 15 Issue 24, p2815 

    Hypertension is one of the major risk factors for cardiovascular disease. Angiotensin receptor blockers (ARBs) are a class of antihypertensive drugs with established efficacy and favorable safety profile. Telmisartan, a member of the ARB family, holds some additional traits which differentiate...

  • Combination therapy for hypertension. Elliott, William T. // Infectious Disease Alert;Feb2009 Pharmacology Watch, p1 

    The article discusses research being done on the effectiveness of benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. It references a study by K. Jamerson and colleagues published in a 2008 issue of the "New England Journal of Medicine." For the study,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics